Table 2.

“Did your approach to screening patients for colorectal cancer change at all as a result of the COVID-19 pandemic? If it did not – please say so. If it did change – how?”

Theme	Quotes from practices
Shifted focus from preventive screenings	“We continued to offer FIT kits but focused mainly on sick or immediate appointments.” “Our focus was on outreach instead of in-office screening.”
Change in the number of FIT kits and commercial FIT-DNA tests that were mailed	“We focused solely on mailing FIT kits because patients could not come in for colonoscopies and tripled the amount of kits mailed during this time, with roughly an 80% return rate.” “We printed lists of everyone who was due and created … [commercial FIT-DNA] orders for patients … mailed letters to those who already had kits but hadn't completed them, and those with old FIT kits received a new … [commercial FIT-DNA] order.” “We pulled back on mailing FIT kits because results are run by an internal lab and there were concerns about exposure [to COVID-19] with receiving returned sample.”

FIT, fecal immunochemical test.